Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - CHAMPIONS ONCOLOGY, INC. | c11135exv99w1.htm |
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 14, 2011
CHAMPIONS BIOTECHNOLOGY,
INC.
(Exact name of registrant as
specified in its charter)
| Delaware | 0-17263 | 52-1401755 | ||
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| Science and Technology Park
at Johns Hopkins 855 N. Wolfe Street, Suite 619, Baltimore, MD |
21205 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (410) 369-0365
| Inapplicable |
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
INFORMATION TO BE INCLUDED IN THE REPORT
| Item 5.02. |
Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
|
On January 14, 2011, Champions Biotechnology, Inc. (the “Company”) announced the resignation of Mark Schonau as Chief Financial Officer effective January 17, 2011. The Company is currently conducting a search for a new Chief Financial Officer.
A copy of the Company’s press release announcing the resignation of Mr. Schonau is attached hereto as Exhibit 99.1.
| Item 9.01. |
Financial
Statements and Exhibits.
|
(d) Exhibits
The following exhibits are filed
herewith:
|
|
Exhibit No.
|
||
|
|
||
|
99.1
|
Press Release dated January 14, 2011 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CHAMPIONS BIOTECHNOLOGY, INC. (Registrant) |
||||
| Date: January 18, 2011 | By: | /s/ Joel Ackerman | ||
| Chief Executive Officer | ||||